Response: Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: how important is internal dosimetry?

We are grateful to Mr Trauernicht and Dr du Toit for their letter to the editor written on the recently published South African practice guidelines on peptide radionuclide therapy of neuroendocrine tumors.1 In the letter, they express concern that internal dosimetry was discussed in “only a single short paragraph” and that this may create an impression that “internal dosimetry assessment is just an optional extra.” The authors drew a contrast between the South African guidelines and the joint International Atomic Energy Agency (IAEA), European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular  Imaging guidelines published earlier where “a whole section on dosimetry” was included.2